Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Thermo Fisher Scientific is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services…
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 125,000
- Headquarters
- Waltham, MA
Similar stocks
What’s behind the score
Valuation
P/E 37.1 — lower than 43% of Healthcare peers
P/B 4.8 — lower than 39% of Healthcare peers
P/S 5.5 — lower than 40% of Healthcare peers
EV/EBITDA 25.0 — lower than 10% of Healthcare peers
EV/Revenue 6.3 — lower than 40% of Healthcare peers
PEG 2.0 — lower than 26% of Healthcare peers
FCF yield 2.4% — higher than 21% of Healthcare peers
Profitability & quality
Gross margin 41.0% — higher than 23% of Healthcare peers
Operating margin 18.8% — higher than 40% of Healthcare peers
Net margin 15.0% — higher than 60% of Healthcare peers
ROE 13.5% — higher than 56% of Healthcare peers
ROA 5.1% — higher than 34% of Healthcare peers
Free cash flow is 90% of reported net income
Financial health
Debt/equity 0.8 — lower than 22% of Healthcare peers
Current ratio 1.55 — higher than 59% of Healthcare peers
Quick ratio 1.01 — higher than 59% of Healthcare peers
Cash/debt 0.10 — higher than 21% of Healthcare peers
Debt/EBITDA 3.62 — lower than 10% of Healthcare peers
Growth
Revenue growth 10.5% YoY — higher than 70% of Healthcare peers
Earnings growth 9.4% YoY — higher than 35% of Healthcare peers
Ownership & investor activity
Payout ratio 9.7% — somewhat unusual vs Healthcare peers
Net insider selling, -2.2% of insider shares
Institutions net sold, -11.7% of shares held
Insiders hold 0.1% of shares outstanding
1.5% of float sold short
Momentum
Above its 50- & 200-day averages
95% of the way from its 52-week low to high